These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 26810844)
1. Age-related Qualitative Histological and Quantitative Stereological Changes in the Equine Pituitary. Leitenbacher J; Herbach N J Comp Pathol; 2016; 154(2-3):215-24. PubMed ID: 26810844 [TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical localization of adrenocorticotropic hormone-immunoreactive cells of the pars intermedia in thoroughbreds. Okada T; Shimomuro T; Oikawa M; Nambo Y; Kiso Y; Morikawa Y; Liptrap RM; Yamashiro S; Little PB; Sasaki F Am J Vet Res; 1997 Aug; 58(8):920-4. PubMed ID: 9256982 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of pituitary gland anatomy and histopathologic findings in clinically normal horses and horses and ponies with pituitary pars intermedia adenoma. van der Kolk JH; Heinrichs M; van Amerongen JD; Stooker RC; in de Wal LJ; van den Ingh TS Am J Vet Res; 2004 Dec; 65(12):1701-7. PubMed ID: 15631037 [TBL] [Abstract][Full Text] [Related]
4. Bioactive and immunoreactive adrenocorticotropin in normal equine pituitary and in pituitary tumors of horses with Cushing's disease. Orth DN; Nicholson WE Endocrinology; 1982 Aug; 111(2):559-63. PubMed ID: 6284484 [TBL] [Abstract][Full Text] [Related]
5. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction. Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825 [TBL] [Abstract][Full Text] [Related]
6. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants. McFarlane D; Beech J; Cribb A Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743 [TBL] [Abstract][Full Text] [Related]
7. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571 [TBL] [Abstract][Full Text] [Related]
8. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction. Pease AP; Schott HC; Howey EB; Patterson JS J Vet Intern Med; 2011; 25(5):1144-51. PubMed ID: 21985144 [TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses. Heinrichs M; Baumgärtner W; Capen CC Vet Pathol; 1990 Nov; 27(6):419-25. PubMed ID: 2177580 [TBL] [Abstract][Full Text] [Related]
10. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia. Beech J; Boston R; Lindborg S; Russell GE J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045 [TBL] [Abstract][Full Text] [Related]
11. Agreement in histologic assessments of the pituitary pars intermedia in aged horses. McFarlane D; Miller LM; Craig LE; Dybdal NO; Habecker PL; Miller MA; Patterson JS; Cribb AE Am J Vet Res; 2005 Dec; 66(12):2055-9. PubMed ID: 16379646 [TBL] [Abstract][Full Text] [Related]
12. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses. McGowan TW; Pinchbeck GP; McGowan CM Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955 [TBL] [Abstract][Full Text] [Related]
13. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction. McFarlane D; Holbrook TC J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032 [TBL] [Abstract][Full Text] [Related]
14. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757 [TBL] [Abstract][Full Text] [Related]
15. Adenomas of the pars intermedia associated with hyperglycemia and glycosuria in two horses. Loeb WF; Capen CC; Johnson LE Cornell Vet; 1966 Oct; 56(4):623-39. PubMed ID: 6008349 [No Abstract] [Full Text] [Related]
16. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses. McFarlane D; Cribb AE Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648 [TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging of the normal equine pituitary gland. Hobbs KJ; Porter E; Wait C; Dark M; MacKay RJ Vet Radiol Ultrasound; 2022 Jul; 63(4):450-455. PubMed ID: 35188303 [TBL] [Abstract][Full Text] [Related]
18. Comparative immunohistochemical study of stellate cells in normal canine and equine adenohypophyses and in pituitary tumours. Méndez A; Martín de las Mulas J; Bautista MJ; Chacón F; Millán Y; Fondevila D; Pumarola M J Comp Pathol; 1998 Jan; 118(1):29-40. PubMed ID: 9500236 [TBL] [Abstract][Full Text] [Related]
19. Suspensory ligament degeneration associated with pituitary pars intermedia dysfunction in horses. Hofberger S; Gauff F; Licka T Vet J; 2015 Mar; 203(3):348-50. PubMed ID: 25641552 [TBL] [Abstract][Full Text] [Related]
20. Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction. Huang L; Palmieri C; Bertin FR Res Vet Sci; 2022 Dec; 152():427-433. PubMed ID: 36126509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]